HUTCHMED (CHINA) LIMITED

Analyst Reco. HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Market Closed - London S.E. Other stock markets 11:35:24 2024-05-07 am EDT			5-day change	1st Jan Change
308 ^GBX	-0.65%		+3.53%	+8.83%

Apr. 26	EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	MT
Apr. 26	Hutchmed notes CHMP's positive opinion for fruiquintinib approval	AN

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Deutsche Bank Upgrades HUTCHMED to Buy From Hold, Adjusts Price Target to $22.10 From $20	Nov. 24	MT
Goldman Sachs Adjusts Price Target on HUTCHMED (China) to $17 From $15, Maintains Neutral Rating	Nov. 10	MT
Hutchmed Says Platelet Disorder Drug Increased Durable Response Rate in Phase 3 Trial	23-08-21	MT
Goldman Sachs Adjusts HUTCHMED (China)'s Price Target to $16 From $14, Maintains Neutral Rating	22-08-09	MT
AstraZeneca Says Lung Cancer Combination Therapy Showed 49% Objective Response Rate	22-08-08	MT
AstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Trial	22-08-08	MT
Hutchmed Says Phase 2 Study to Treat Patients With MET-Driven Non-Small Lung Cancer Shows Improved Response Rates	22-07-13	MT
Deutsche Bank Downgrades HUTCHMED to Hold From Buy, Adjusts Price Target to $20 From $37	22-05-05	MT
HUTCHMED CHINA : Goldman Sachs Downgrades Hutchison China MediTech to Neutral From Buy	21-09-22	MT
HUTCHMED CHINA : Jefferies Initiates Hutchison China MediTech at Buy Rating With $52 Price Target	21-08-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW